文献速递白内障与屈光手术角膜与眼表疾病

服用异维A酸患者行LASIK与PRK的疗效观察

Outcomes of Laser In Situ Keratomileusis and Photorefractive Keratectomy in Patients Taking Isotretinoin.
PubMed 文献 · Am J Ophthalmol · 2018-06-01

这项多中心回顾性介入病例系列纳入服用异维A酸期间接受LASIK或PRK的患者(组1),并与既往服用但近6个月未服药者(组2)比较。共113例219眼,两组在视力、等效球镜、有效性指数、可预测性和安全性指数上无显著差异;仅PRK亚组中组2的有效性指数、术后球镜和散光更优,但差异无临床意义。

要点

  • 服用异维A酸期间行LASIK或PRK未发现显著术中或术后并发症。
  • 组1与组2在视力、等效球镜、有效性指数、可预测性和安全性指数上无显著差异。
  • PRK亚组中组2有效性指数(P = .017)、术后球镜(P = .041)和散光(P < .001)更优,但差异无临床意义。

核心结论

  • 在所选服用异维A酸的患者中,LASIK和PRK可有效且安全地进行;对某些全身用药的绝对排除应重新考虑。

研究设计与样本

  • 多中心、回顾性、介入性病例系列,纳入2003年1月至2017年9月服用异维A酸期间行LASIK或PRK的患者(组1),并与既往服用但近6个月未服药者(组2)连续纳入比较,共113例219眼。

主要发现

  • 未发现显著的术中或术后并发症。
  • 两组在视力、术后等效球镜、有效性指数、可预测性和安全性指数方面无显著差异。
  • 仅PRK患者中,组2的有效性指数(P = .017)、术后球镜(P = .041)和术后散光(P < .001)优于组1,但差异无临床意义。

关键数值与推荐

  • 组1为服用异维A酸期间手术者,组2为既往服用但近6个月未服药者。
  • PRK亚组中组2有效性指数P = .017、术后球镜P = .041、术后散光P < .001优于组1,但差异无临床意义。

临床怎么用

  • 在所选服用异维A酸的患者中,LASIK和PRK可有效且安全地进行。
  • 对某些全身用药的绝对排除应重新考虑。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the functional outcomes of laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) in patients taking isotretinoin, which is contraindicated for these procedures. DESIGN: Multicenter, retrospective, interventional case series. METHODS: All patients taking isotretinoin who underwent LASIK or PRK from January 2003 to September 2017 were included (Group 1). Patients were compared with those undergoing LASIK or PRK who had taken isotretinoin previously but not in the previous 6 months (Group 2). Patients were included consecutively. RESULTS: A total of 113 patients (219 eyes) were included. No significant intraoperative or postoperative complications were found. There were no significant differences between the groups in terms of visual acuity, postoperative spherical equivalent, efficacy index, predictability, or safety index. When only PRK patients were taken into account, the efficacy index (P = .017), postoperative sphere (P = .041), and postoperative astigmatism (P < .001) were better in Group 2, although the difference was not clinically relevant. CONCLUSIONS: In our experience, LASIK and PRK can be performed effectively and safely in selected patients taking isotretinoin. The absolute exclusion of certain systemic medications should be reconsidered.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ortega-Usobiaga J, Llovet-Osuna F, Djodeyre MR, et al. Outcomes of Laser In Situ Keratomileusis and Photorefractive Keratectomy in Patients Taking Isotretinoin. Am J Ophthalmol. 2018. PMID: 29772222. doi:10.1016/j.ajo.2018.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。